KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares Issued
Ratios

Jazz Pharmaceuticals (JAZZ) Other Gross PP&E Adjustments (2016 - 2025)

Historic Other Gross PP&E Adjustments for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to $130.4 million.

  • Jazz Pharmaceuticals' Other Gross PP&E Adjustments rose 3873.97% to $130.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $130.4 million, marking a year-over-year increase of 3873.97%. This contributed to the annual value of $255.6 million for FY2024, which is 3503.92% up from last year.
  • As of Q3 2025, Jazz Pharmaceuticals' Other Gross PP&E Adjustments stood at $130.4 million, which was up 3873.97% from -$52.1 million recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Other Gross PP&E Adjustments ranged from a high of $255.6 million in Q4 2024 and a low of -$221.1 million during Q1 2024
  • Moreover, its 5-year median value for Other Gross PP&E Adjustments was -$27.4 million (2022), whereas its average is $15.2 million.
  • Its Other Gross PP&E Adjustments has fluctuated over the past 5 years, first skyrocketed by 152275.01% in 2021, then plummeted by 14499.51% in 2024.
  • Quarter analysis of 5 years shows Jazz Pharmaceuticals' Other Gross PP&E Adjustments stood at $218.3 million in 2021, then rose by 0.57% to $219.6 million in 2022, then fell by 13.81% to $189.3 million in 2023, then soared by 35.04% to $255.6 million in 2024, then tumbled by 48.99% to $130.4 million in 2025.
  • Its last three reported values are $130.4 million in Q3 2025, -$52.1 million for Q2 2025, and -$174.0 million during Q1 2025.